Skip to content

Author

Nadine A. Jackson

We have 4 of 9 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Abstract C082: Advancing equitable cancer clinical trial access through workforce education: Results of a pre-post training evaluation

Demographic disparities in oncology clinical trial participation persist; while research staff perform key research functions, there are few data regarding whether training programs improve their knowledge of trial-related enrollment disparities. We evaluated the impact of an oncology research staff traini...

Kristen A. Legor, Cameron Keith, Emerald Littlejohn et al. · 0 citations
Sep 2026

Abstract A127: Targeting replication stress in pancreatic cancer: results of a phase 1b trial of azenosertib and gemcitabine in second line pancreatic cancer after progression on FOLFIRINOX

The combination of azenosertib and gemcitabine was associated with substantial myelosuppression in patients with metastatic PDAC previously treated with FOLFIRINOX, limiting further clinical evaluation of this dosing strategy.

B. Huffman, Haeseong Park, N. Jackson et al. · 0 citations
Review Open access Oct 2026

Leveraging patient-reported and health record data to monitor oncofertility care among adults with cancer: A proof-of-concept study.

A proof-of-concept study that demonstrates the feasibility of leveraging ePROs linked with EHR data to identify adults with cancer experiencing fertility concerns and characterize subsequent oncofertility care and inform interventions to improve fertility counseling, referral, and navigation for adults with cancer.

Nadine A. Jackson, B. A. Neville, J. Stal et al. · 0 citations
Open access Aug 2026

Addition of High-Dose Vitamin D3 to Standard Treatment in Patients with Metastatic Colorectal Cancer: The SOLARIS Randomized Clinical Trial (Alliance A021703)

High-dose vitamin D3 added to standard treatment improved progression-free survival (PFS) compared to standard-dose vitamin D3 in patients with metastatic colorectal cancer (mCRC) in a phase 2 randomized clinical trial.

K. Ng, F. Ou, T. Zemla et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.